Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?

Keyphrases

• Cytogenetic Abnormalities 100%
• Cytogenetic Study 100%
• Morphological Abnormalities 100%
• Lymph Node 66%
• Chemotherapy 66%
• Bone Marrow 66%
• Morphological Changes 66%
• Hematologic 66%
• Burkitt Lymphoma 66%
• Pleural Effusion 66%
• 2-cycles 66%
• High-grade non-Hodgkin Lymphoma 66%
• Effusion Lymphoma 66%
• Cytogenetic Assay 66%
• Patient Care 33%
• Fludarabine 33%
• Malignancy 33%
• Disease Progression 33%
• Cyclophosphamide 33%
• Prednisone 33%
• Genetic Changes 33%
• AIDS/HIV 33%
• Patient Management 33%
• Patient Prognosis 33%
• Non-Hodgkin Lymphoma 33%
• Malignant Disease 33%
• Clinical Response 33%
• Doxorubicin 33%
• Disease Management 33%
• Mitotic Figures 33%
• Natural Killer 33%
• Neoplastic Tissue 33%
• Leukemia-lymphoma 33%
• Lymphoma Patients 33%
• Ascitic Fluid 33%
• Normal Bone Marrow 33%
• Malignant Disorders 33%
• Blastic 33%
• Bone Marrow Analysis 33%
• High-grade Lymphoma 33%
• Ascitis 33%
• Hematological Changes 33%

Medicine and Dentistry

• Non-Hodgkin Lymphoma 100%
• Morphologic Abnormality 100%
• Morphology 75%
• Lymph Node 50%
• Burkitt's Lymphoma 50%
• Pleura Effusion 50%
• Diseases 25%
• Cancer 25%
• Patient Care 25%
• Fludarabine 25%
• Human immunodeficiency virus 25%
• Cyclophosphamide 25%
• Prednisone 25%
• Leukemia 25%
• Disease 25%
• Doxorubicin 25%
• Vincristine 25%
• Gene Mutation 25%
• Disease Management 25%
• CHOP 25%